Vera Therapeutics Inc.
07/07/2026 | Press release | Distributed by Public on 07/07/2026 10:46
Material Event (Form 8-K)
Item 8.01 Other Events.
On July 7, 2026, Vera Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted TRUTAKNA™ (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.
Vera Therapeutics Inc. published this content on July 07, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 07, 2026 at 16:46 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]